{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T16:34:46Z","timestamp":1778603686943,"version":"3.51.4"},"reference-count":102,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Continuum"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1212\/con.0000000000000337","type":"journal-article","created":{"date-parts":[[2016,6,4]],"date-time":"2016-06-04T11:57:05Z","timestamp":1465041425000},"page":"864-896","source":"Crossref","is-referenced-by-count":23,"title":["Neuromyelitis Optica Spectrum Disorders"],"prefix":"10.1212","volume":"22","author":[{"given":"Ilana Katz","family":"Sand","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"4","key":"e_1_3_1_2_2","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon VA","year":"2005","unstructured":"Lennon VA Kryzer TJ Pittock SJ IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005;202(4):473\u2013477. doi:10.1084\/jem.20050304.","journal-title":"J Exp Med"},{"issue":"7","key":"e_1_3_1_3_2","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1001\/archneur.63.7.964","article-title":"Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression","volume":"63","author":"Pittock SJ","year":"2006","unstructured":"Pittock SJ Weinshenker BG Lucchinetti CF Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol 2006;63(7):964\u2013968. doi:10.1001\/archneur.63.7.964.","journal-title":"Arch Neurol"},{"issue":"5","key":"e_1_3_1_4_2","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/brain\/awl371","article-title":"Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis","volume":"130","author":"Roemer SF","year":"2007","unstructured":"Roemer SF Parisi JE Lennon VA Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 2007;130(pt 5):1194\u20131205. doi:10.1093\/brain\/awl371.","journal-title":"Brain"},{"issue":"24","key":"e_1_3_1_5_2","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1212\/01.WNL.0000289761.64862.ce","article-title":"Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica","volume":"69","author":"Hinson SR","year":"2007","unstructured":"Hinson SR Pittock SJ Lucchinetti CF Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology 2007;69(24):2221\u20132231. doi:01.WNL.0000289761.64862.ce.","journal-title":"Neurology"},{"issue":"5","key":"e_1_3_1_6_2","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s10072-014-1635-6","article-title":"First-ever optic neuritis: distinguishing subsequent neuromyelitis optica from multiple sclerosis","volume":"35","author":"Lim YM","year":"2014","unstructured":"Lim YM Pyun SY Lim HT First-ever optic neuritis: distinguishing subsequent neuromyelitis optica from multiple sclerosis. Neurol Sci 2014;35(5):781\u2013783. doi:10.1007\/s10072-014-1635-6.","journal-title":"Neurol Sci"},{"issue":"5","key":"e_1_3_1_7_2","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","article-title":"The clinical course of neuromyelitis optica (Devic\u2019s syndrome)","volume":"53","author":"Wingerchuk DM","year":"1999","unstructured":"Wingerchuk DM Hogancamp WF O\u2019Brien PC Weinshenker BG. The clinical course of neuromyelitis optica (Devic\u2019s syndrome). Neurology 1999;53(5):1107\u20131114. doi:10.1212\/WNL.53.5.1107.","journal-title":"Neurology"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-10-45"},{"issue":"2","key":"e_1_3_1_9_2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/WNO.0b013e318283c3ed","article-title":"Distinguishing optic neuritis in neuromyelitis optica spectrum disease from multiple sclerosis: a novel magnetic resonance imaging scoring system","volume":"33","author":"Storoni M","year":"2013","unstructured":"Storoni M Davagnanam I Radon M Distinguishing optic neuritis in neuromyelitis optica spectrum disease from multiple sclerosis: a novel magnetic resonance imaging scoring system. J Neuroophthalmol 2013;33(2):123\u2013127. doi:10.1097\/WNO.0b013e318283c3ed.","journal-title":"J Neuroophthalmol"},{"issue":"3","key":"e_1_3_1_10_2","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/WNO.0b013e318254c62d","article-title":"Magnetic resonance imaging of optic neuritis in patients with neuromyelitis optica versus multiple sclerosis","volume":"32","author":"Khanna S","year":"2012","unstructured":"Khanna S Sharma A Huecker J Magnetic resonance imaging of optic neuritis in patients with neuromyelitis optica versus multiple sclerosis. J Neuroophthalmol 2012;32(3):216\u2013220. doi:10.1097\/WNO.0b013e318254c62d.","journal-title":"J Neuroophthalmol"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-444-52001-2.00027-3"},{"issue":"9","key":"e_1_3_1_12_2","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nrneurol.2014.129","article-title":"Pain in neuromyelitis optica\u2014prevalence, pathogenesis and therapy","volume":"10","author":"Bradl M","year":"2014","unstructured":"Bradl M Kanamori Y Nakashima I Pain in neuromyelitis optica\u2014prevalence, pathogenesis and therapy. Nat Rev Neurol 2014;10(9):529\u2013536. doi:10.1038\/nrneurol.2014.129.","journal-title":"Nat Rev Neurol"},{"issue":"4","key":"e_1_3_1_13_2","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1177\/1352458512457720","article-title":"Neuropathic pruritus (itch) in neuromyelitis optica","volume":"19","author":"Elsone L","year":"2013","unstructured":"Elsone L Townsend T Mutch K Neuropathic pruritus (itch) in neuromyelitis optica. Mult Scler 2013;19(4):475\u2013479. doi:10.1177\/1352458512457720.","journal-title":"Mult Scler"},{"issue":"8","key":"e_1_3_1_14_2","first-page":"1026","article-title":"Painful tonic spasm in neuromyelitis optica: incidence, diagnostic utility, and clinical characteristics","volume":"69","author":"Kim SM","year":"2012","unstructured":"Kim SM Go MJ Sung JJ Painful tonic spasm in neuromyelitis optica: incidence, diagnostic utility, and clinical characteristics. Arch Neurol 2012;69(8):1026\u20131031. doi:10.1001\/archneurol.2012.112.","journal-title":"Arch Neurol"},{"issue":"11","key":"e_1_3_1_15_2","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1212\/WNL.0000000000001367","article-title":"MRI characteristics of neuromyelitis optica spectrum disorder: an international update","volume":"84","author":"Kim HJ","year":"2015","unstructured":"Kim HJ Paul F Lana-Peixoto MA MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology 2015;84(11):1165\u20131173. doi:10.1212\/WNL.0000000000001367.","journal-title":"Neurology"},{"issue":"1","key":"e_1_3_1_16_2","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jns.2010.02.026","article-title":"Characteristic linear lesions and longitudinally extensive spinal cord lesions in Chinese patients with neuromyelitis optica","volume":"293","author":"Lu Z","year":"2010","unstructured":"Lu Z Qiu W Zou Y Characteristic linear lesions and longitudinally extensive spinal cord lesions in Chinese patients with neuromyelitis optica. J Neurol Sci 2010;293(1\u20132):92\u201396. doi:10.1016\/j.jns.2010.02.026.","journal-title":"J Neurol Sci"},{"issue":"1","key":"e_1_3_1_17_2","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1001\/jamaneurol.2014.2137","article-title":"Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders","volume":"72","author":"Flanagan EP","year":"2015","unstructured":"Flanagan EP Weinshenker BG Krecke KN Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders. JAMA Neurol 2015;72(1):81\u201387. doi:10.1001\/jamaneurol.2014.2137.","journal-title":"JAMA Neurol"},{"issue":"2","key":"e_1_3_1_18_2","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00415-008-0545-z","article-title":"Preferential spinal central gray matter involvement in neuromyelitis optica. An MRI study","volume":"255","author":"Nakamura M","year":"2008","unstructured":"Nakamura M Miyazawa I Fujihara K Preferential spinal central gray matter involvement in neuromyelitis optica. An MRI study. J Neurol 2008;255(2):163\u2013170. doi:10.1007\/s00415-008-0545-z.","journal-title":"J Neurol"},{"issue":"1","key":"e_1_3_1_19_2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/ane.12354","article-title":"Spinal cord ring enhancement in patients with neuromyelitis optica","volume":"132","author":"Yokote H","year":"2015","unstructured":"Yokote H Nose Y Ishibashi S Spinal cord ring enhancement in patients with neuromyelitis optica. Acta Neurol Scand 2015;132(1):37\u201341. doi:10.1111\/ane.12354.","journal-title":"Acta Neurol Scand"},{"issue":"9","key":"e_1_3_1_20_2","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1212\/01.wnl.0000183151.19351.82","article-title":"Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica","volume":"65","author":"Misu T","year":"2005","unstructured":"Misu T Fujihara K Nakashima I Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica. Neurology 2005;65(9):1479\u20131482. doi:10.1212\/01.wnl.0000183151.19351.82.","journal-title":"Neurology"},{"issue":"5","key":"e_1_3_1_21_2","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/ana.22121","article-title":"Intractable vomiting as the initial presentation of neuromyelitis optica","volume":"68","author":"Apiwattanakul M","year":"2010","unstructured":"Apiwattanakul M Popescu BF Matiello M Intractable vomiting as the initial presentation of neuromyelitis optica. Ann Neurol 2010;68(5):757\u2013761. doi:10.1002\/ana.22121.","journal-title":"Ann Neurol"},{"issue":"9","key":"e_1_3_1_22_2","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1136\/jnnp.2008.145391","article-title":"Intractable hiccup and nausea in neuromyelitis optica with anti-aquaporin-4 antibody: a herald of acute exacerbations","volume":"79","author":"Takahashi T","year":"2008","unstructured":"Takahashi T Miyazawa I Misu T Intractable hiccup and nausea in neuromyelitis optica with anti-aquaporin-4 antibody: a herald of acute exacerbations. J Neurol Neurosurg Psychiatry 2008;79(9):1075\u20131078. doi:10.1136\/jnnp.2008.145391.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"14","key":"e_1_3_1_23_2","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1212\/WNL.0b013e318214332c","article-title":"Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications","volume":"76","author":"Popescu BF","year":"2011","unstructured":"Popescu BF Lennon VA Parisi JE Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications. Neurology 2011;76(14):1229\u20131237. doi:10.1212\/WNL.0b013e318214332c.","journal-title":"Neurology"},{"issue":"7","key":"e_1_3_1_24_2","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1177\/1352458513507822","article-title":"Brainstem manifestations in neuromyelitis optica: a multicenter study of 258 patients","volume":"20","author":"Kremer L","year":"2014","unstructured":"Kremer L Mealy M Jacob A Brainstem manifestations in neuromyelitis optica: a multicenter study of 258 patients. Mult Scler 2014;20(7):843\u2013847. doi:10.1177\/1352458513507822.","journal-title":"Mult Scler"},{"issue":"4","key":"e_1_3_1_25_2","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.msard.2014.04.002","article-title":"Pathologic yawning in neuromyelitis optica spectrum disorders","volume":"3","author":"Lana-Peixoto MA","year":"2014","unstructured":"Lana-Peixoto MA Callegaro D Talim N Pathologic yawning in neuromyelitis optica spectrum disorders. Mult Scler Relat Disord 2014;3(4):527\u2013532. doi:10.1016\/j.msard.2014.04.002.","journal-title":"Mult Scler Relat Disord"},{"issue":"6","key":"e_1_3_1_26_2","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1136\/jnnp.2008.157693","article-title":"Symptomatic, radiological and pathological involvement of the hypothalamus in neuromyelitis optica","volume":"80","author":"Viegas S","year":"2009","unstructured":"Viegas S Weir A Esiri M Symptomatic, radiological and pathological involvement of the hypothalamus in neuromyelitis optica. J Neurol Neurosurg Psychiatry 2009;80(6):679\u2013682. doi:10.1136\/jnnp.2008.157693.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"e_1_3_1_27_2","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00415-009-0139-4","article-title":"Narcolepsy as an initial manifestation of neuromyelitis optica with anti-aquaporin-4 antibody","volume":"256","author":"Baba T","year":"2009","unstructured":"Baba T Nakashima I Kanbayashi T Narcolepsy as an initial manifestation of neuromyelitis optica with anti-aquaporin-4 antibody. J Neurol 2009;256(2):287\u2013288. doi:10.1007\/s00415-009-0139-4.","journal-title":"J Neurol"},{"issue":"7","key":"e_1_3_1_28_2","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1177\/1352458515569100","article-title":"Neuromyelitis optica spectrum disorder presenting with repeated hypersomnia due to involvement of the hypothalamus and hypothalamus-amygdala linkage","volume":"21","author":"Kume K","year":"2015","unstructured":"Kume K Deguchi K Ikeda K Neuromyelitis optica spectrum disorder presenting with repeated hypersomnia due to involvement of the hypothalamus and hypothalamus-amygdala linkage. Mult Scler 2015;21(7):960\u2013962. doi:10.1177\/1352458515569100.","journal-title":"Mult Scler"},{"issue":"10","key":"e_1_3_1_29_2","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1001\/archneurol.2012.300","article-title":"Hypothermia, hypotension, hypersomnia, and obesity associated with hypothalamic lesions in a patient positive for the anti-aquaporin 4 antibody: a case report and literature review","volume":"69","author":"Suzuki K","year":"2012","unstructured":"Suzuki K Nakamura T Hashimoto K Hypothermia, hypotension, hypersomnia, and obesity associated with hypothalamic lesions in a patient positive for the anti-aquaporin 4 antibody: a case report and literature review. Arch Neurol 2012;69(10):1355\u20131359. doi: 10.1001\/archneurol.2012.300.","journal-title":"Arch Neurol"},{"issue":"8","key":"e_1_3_1_30_2","doi-asserted-by":"crossref","first-page":"599","DOI":"10.5692\/clinicalneurol.51.599","article-title":"Neuromyelitis optica with syndrome of inappropriate secretion of antidiuretic hormone and hypersomnia associated with bilateral hypothalamic lesions: a case report","volume":"51","author":"Nakano T","year":"2011","unstructured":"Nakano T Fujimoto T Fukuda Y Neuromyelitis optica with syndrome of inappropriate secretion of antidiuretic hormone and hypersomnia associated with bilateral hypothalamic lesions: a case report. Rinsho Shinkeigaku 2011;51(8):599\u2013602. doi:JST.JSTAGE\/clinicalneurol\/51.599.","journal-title":"Rinsho Shinkeigaku"},{"issue":"2","key":"e_1_3_1_31_2","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s13760-012-0029-x","article-title":"Consciousness disturbance and poikilothermia revealing brain involvement in neuromyelitis optica","volume":"112","author":"Yildiz OK","year":"2012","unstructured":"Yildiz OK Cevik S Oztoprak I. Consciousness disturbance and poikilothermia revealing brain involvement in neuromyelitis optica. Acta Neurol Belg 2012;112(2):213\u2013215. doi:10.1007\/s13760-012-0029-x.","journal-title":"Acta Neurol Belg"},{"issue":"4","key":"e_1_3_1_32_2","doi-asserted-by":"crossref","first-page":"489","DOI":"10.2169\/internalmedicine.52.8992","article-title":"Anorexia heralding the onset of neuromyelitis optica","volume":"52","author":"Iorio R","year":"2013","unstructured":"Iorio R Plantone D Damato V Paola Batocchi A. Anorexia heralding the onset of neuromyelitis optica. Intern Med 2013;52(4):489\u2013491. doi:DN\/JST.JSTAGE\/internalmedicine\/52.8992.","journal-title":"Intern Med"},{"issue":"3","key":"e_1_3_1_33_2","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1159\/000334129","article-title":"Anti-aquaporin-4 antibody-positive neuromyelitis optica presenting with syndrome of inappropriate antidiuretic hormone secretion as an initial manifestation","volume":"3","author":"Nakajima H","year":"2011","unstructured":"Nakajima H Fujiki Y Ito T Anti-aquaporin-4 antibody-positive neuromyelitis optica presenting with syndrome of inappropriate antidiuretic hormone secretion as an initial manifestation. Case Rep Neurol 2011;3(3):263\u2013267. doi:10.1159\/000334129.","journal-title":"Case Rep Neurol"},{"issue":"12","key":"e_1_3_1_34_2","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1007\/s00415-011-6112-z","article-title":"Anhidrosis associated with hypothalamic lesions related to anti-aquaporin 4 autoantibody","volume":"258","author":"Sekiguchi T","year":"2011","unstructured":"Sekiguchi T Ishibashi S Kubodera T Anhidrosis associated with hypothalamic lesions related to anti-aquaporin 4 autoantibody. J Neurol 2011;258(12):2293\u20132295. doi:10.1007\/s00415-011-6112-z.","journal-title":"J Neurol"},{"issue":"6","key":"e_1_3_1_35_2","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1177\/1352458513506953","article-title":"The usefulness of brain MRI at onset in the differentiation of multiple sclerosis and seropositive neuromyelitis optica spectrum disorders","volume":"20","author":"Huh SY","year":"2014","unstructured":"Huh SY Min JH Kim W The usefulness of brain MRI at onset in the differentiation of multiple sclerosis and seropositive neuromyelitis optica spectrum disorders. Mult Scler 2014;20(6):695\u2013704. doi:10.1177\/1352458513506953.","journal-title":"Mult Scler"},{"issue":"8","key":"e_1_3_1_36_2","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1212\/01.wnl.0000343001.36493.ae","article-title":"Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders","volume":"72","author":"Maga\u00f1a SM","year":"2009","unstructured":"Maga\u00f1a SM Matiello M Pittock SJ Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders. Neurology 2009;72(8):712\u2013717. doi:10.1212\/01.wnl.0000343001.36493.ae.","journal-title":"Neurology"},{"issue":"9","key":"e_1_3_1_37_2","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1177\/1352458511404917","article-title":"Brain abnormalities as an initial manifestation of neuromyelitis optica spectrum disorder","volume":"17","author":"Kim W","year":"2011","unstructured":"Kim W Kim SH Lee SH Brain abnormalities as an initial manifestation of neuromyelitis optica spectrum disorder. Mult Scler 2011;17(9):1107\u20131112. doi:10.1177\/1352458511404917.","journal-title":"Mult Scler"},{"issue":"20","key":"e_1_3_1_38_2","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1212\/WNL.0000000000000428","article-title":"Hydrocephalus in neuromyelitis optica","volume":"82","author":"Clardy SL","year":"2014","unstructured":"Clardy SL Lucchinetti CF Krecke KN Hydrocephalus in neuromyelitis optica. Neurology 2014;82(20):1841\u20131843. doi:10.1212\/WNL.0000000000000428.","journal-title":"Neurology"},{"issue":"8","key":"e_1_3_1_39_2","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1001\/jamaneurol.2014.775","article-title":"Autoimmune aquaporin-4 myopathy in neuromyelitis optica spectrum","volume":"71","author":"Guo Y","year":"2014","unstructured":"Guo Y Lennon VA Popescu BF Autoimmune aquaporin-4 myopathy in neuromyelitis optica spectrum. JAMA Neurol 2014;71(8):1025\u20131029. doi:10.1001\/jamaneurol.2014.775.","journal-title":"JAMA Neurol"},{"issue":"18","key":"e_1_3_1_40_2","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.2169\/internalmedicine.51.7898","article-title":"HyperCKemia related to the initial and recurrent attacks of neuromyelitis optica","volume":"51","author":"Deguchi S","year":"2012","unstructured":"Deguchi S Deguchi K Sato K HyperCKemia related to the initial and recurrent attacks of neuromyelitis optica. Intern Med 2012;51(18):2617\u20132620. doi:DN\/JST.JSTAGE\/internalmedicine\/51.7898.","journal-title":"Intern Med"},{"issue":"19","key":"e_1_3_1_41_2","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1212\/WNL.0b013e3181dd445b","article-title":"Neuromyelitis optica preceded by hyperCKemia episode","volume":"74","author":"Suzuki N","year":"2010","unstructured":"Suzuki N Takahashi T Aoki M Neuromyelitis optica preceded by hyperCKemia episode. Neurology 2010;74(19):1543\u20131545. doi:10.1212\/WNL.0b013e3181dd445b.","journal-title":"Neurology"},{"issue":"10","key":"e_1_3_1_42_2","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1177\/1352458510376640","article-title":"Characteristic brain magnetic resonance imaging abnormalities in central nervous system aquaporin-4 autoimmunity","volume":"16","author":"Kim W","year":"2010","unstructured":"Kim W Park MS Lee SH Characteristic brain magnetic resonance imaging abnormalities in central nervous system aquaporin-4 autoimmunity. Mult Scler 2010;16(10):1229\u20131236. doi:10.1177\/1352458510376640.","journal-title":"Mult Scler"},{"issue":"3","key":"e_1_3_1_43_2","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1001\/archneur.63.3.390","article-title":"Brain abnormalities in neuromyelitis optica","volume":"63","author":"Pittock SJ","year":"2006","unstructured":"Pittock SJ Lennon VA Krecke K Brain abnormalities in neuromyelitis optica. Arch Neurol 2006;63(3):390\u2013396. doi:10.1001\/archneur.63.3.390.","journal-title":"Arch Neurol"},{"issue":"6","key":"e_1_3_1_44_2","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1177\/1352458509103301","article-title":"Occurrence of acute large and edematous callosal lesions in neuromyelitis optica","volume":"15","author":"Nakamura M","year":"2009","unstructured":"Nakamura M Misu T Fujihara K Occurrence of acute large and edematous callosal lesions in neuromyelitis optica. Mult Scler 2009;15(6):695\u2013700. doi:10.1177\/1352458509103301.","journal-title":"Mult Scler"},{"issue":"3","key":"e_1_3_1_45_2","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/ana.21753","article-title":"\u201cCloud-like enhancement\u201d is a magnetic resonance imaging abnormality specific to neuromyelitis optica","volume":"66","author":"Ito S","year":"2009","unstructured":"Ito S Mori M Makino T \u201cCloud-like enhancement\u201d is a magnetic resonance imaging abnormality specific to neuromyelitis optica. Ann Neurol 2009;66(3):425\u2013428. doi:10.1002\/ana.21753.","journal-title":"Ann Neurol"},{"issue":"9","key":"e_1_3_1_46_2","doi-asserted-by":"crossref","first-page":"e108320","DOI":"10.1371\/journal.pone.0108320","article-title":"A longitudinal brain magnetic resonance imaging study of neuromyelitis optica spectrum disorder","volume":"9","author":"Kim SH","year":"2014","unstructured":"Kim SH Huh SY Hyun JW A longitudinal brain magnetic resonance imaging study of neuromyelitis optica spectrum disorder. PLoS One 2014;9(9):e108320. doi:10.1371\/journal.pone.0108320.","journal-title":"PLoS One"},{"issue":"7","key":"e_1_3_1_47_2","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1177\/1352458511431730","article-title":"Pencil-thin ependymal enhancement in neuromyelitis optica spectrum disorders","volume":"18","author":"Banker P","year":"2012","unstructured":"Banker P Sonni S Kister I Pencil-thin ependymal enhancement in neuromyelitis optica spectrum disorders. Mult Scler 2012;18(7):1050\u20131053. doi:10.1177\/1352458511431730.","journal-title":"Mult Scler"},{"issue":"3","key":"e_1_3_1_48_2","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1177\/1352458512454772","article-title":"Diffuse and heterogeneous T2-hyperintense lesions in the splenium are characteristic of neuromyelitis optica","volume":"19","author":"Makino T","year":"2013","unstructured":"Makino T Ito S Mori M Diffuse and heterogeneous T2-hyperintense lesions in the splenium are characteristic of neuromyelitis optica. Mult Scler 2013;19(3):308\u2013315. doi:10.1177\/1352458512454772.","journal-title":"Mult Scler"},{"issue":"4","key":"e_1_3_1_49_2","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.msard.2015.06.003","article-title":"Specificity and sensitivity of aquaporin 4 antibody detection tests in patients with neuromyelitis optica: a meta-analysis","volume":"4","author":"Ruiz-Gaviria R","year":"2015","unstructured":"Ruiz-Gaviria R Baracaldo I Casta\u00f1eda C Specificity and sensitivity of aquaporin 4 antibody detection tests in patients with neuromyelitis optica: a meta-analysis. Mult Scler Relat Disord 2015;4(4):345\u2013349. doi:10.1016\/j.msard.2015.06.003.","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"e_1_3_1_50_2","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jns.2011.03.038","article-title":"Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures","volume":"306","author":"Jarius S","year":"2011","unstructured":"Jarius S Paul F Franciotta D Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures. J Neurol Sci 2011;306(1\u20132):82\u201390. doi:10.1016\/j.jns.2011.03.038.","journal-title":"J Neurol Sci"},{"issue":"1","key":"e_1_3_1_51_2","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/jnnp-2014-308984","article-title":"Overlapping CNS inflammatory diseases: differentiating features of NMO and MS","volume":"86","author":"Jury\u0144czyk M","year":"2015","unstructured":"Jury\u0144czyk M Craner M Palace J. Overlapping CNS inflammatory diseases: differentiating features of NMO and MS. J Neurol Neurosurg Psychiatry 2015;86(1):20\u201325. doi:10.1136\/jnnp-2014-308984.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"e_1_3_1_52_2","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1159\/000330240","article-title":"Aquaporin 4 antibodies in the cerebrospinal fluid are helpful in diagnosing Chinese patients with neuromyelitis optica","volume":"19","author":"Long Y","year":"2012","unstructured":"Long Y Qiu W Lu Z Aquaporin 4 antibodies in the cerebrospinal fluid are helpful in diagnosing Chinese patients with neuromyelitis optica. Neuroimmunomodulation 2012;19(2):96\u2013102. doi:10.1159\/000330240.","journal-title":"Neuroimmunomodulation"},{"issue":"5","key":"e_1_3_1_53_2","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1136\/jnnp.2008.150698","article-title":"Marked increase in cerebrospinal fluid glial fibrillar acidic protein in neuromyelitis optica: an astrocytic damage marker","volume":"80","author":"Misu T","year":"2009","unstructured":"Misu T Takano R Fujihara K Marked increase in cerebrospinal fluid glial fibrillar acidic protein in neuromyelitis optica: an astrocytic damage marker. J Neurol Neurosurg Psychiatry 2009;80(5):575\u2013577. doi:10.1136\/jnnp.2008.150698.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"e_1_3_1_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2013.03.020"},{"issue":"12","key":"e_1_3_1_55_2","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1007\/s00415-009-5274-4","article-title":"Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosis","volume":"256","author":"Uzawa A","year":"2009","unstructured":"Uzawa A Mori M Ito M Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosis. J Neurol 2009;256(12):2082\u20132084. doi:10.1007\/s00415-009-5274-4.","journal-title":"J Neurol"},{"issue":"10","key":"e_1_3_1_56_2","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","article-title":"Revised diagnostic criteria for neuromyelitis optica","volume":"66","author":"Wingerchuk DM","year":"2006","unstructured":"Wingerchuk DM Lennon VA Pittock SJ Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66(10):1485\u20131489. doi:10.1212\/01.wnl.0000216139.44259.74.","journal-title":"Neurology"},{"issue":"2","key":"e_1_3_1_57_2","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk DM","year":"2015","unstructured":"Wingerchuk DM Banwell B Bennett JL International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015;85(2):177\u2013189. doi:10.1212\/WNL.0000000000001729.","journal-title":"Neurology"},{"issue":"8","key":"e_1_3_1_58_2","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nrneurol.2014.108","article-title":"The investigation of acute optic neuritis: a review and proposed protocol","volume":"10","author":"Petzold A","year":"2014","unstructured":"Petzold A Wattjes MP Costello F The investigation of acute optic neuritis: a review and proposed protocol. Nat Rev Neurol 2014;10(8):447\u2013458. doi:10.1038\/nrneurol.2014.108.","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"e_1_3_1_59_2","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/brain\/awg045","article-title":"Chronic relapsing inflammatory optic neuropathy (CRION)","volume":"126","author":"Kidd D","year":"2003","unstructured":"Kidd D Burton B Plant GT Graham EM. Chronic relapsing inflammatory optic neuropathy (CRION). Brain 2003;126(pt 2):276\u2013284. doi:10.1093\/brain\/awg045.","journal-title":"Brain"},{"issue":"1","key":"e_1_3_1_60_2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00415-013-6957-4","article-title":"Chronic relapsing inflammatory optic neuropathy: a systematic review of 122 cases reported","volume":"261","author":"Petzold A","year":"2014","unstructured":"Petzold A Plant GT. Chronic relapsing inflammatory optic neuropathy: a systematic review of 122 cases reported. J Neurol 2014;261(1):17\u201326. doi:10.1007\/s00415-013-6957-4.","journal-title":"J Neurol"},{"issue":"3","key":"e_1_3_1_61_2","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/WCO.0000000000000093","article-title":"Longitudinally extensive transverse myelitis","volume":"27","author":"Tobin WO","year":"2014","unstructured":"Tobin WO Weinshenker BG Lucchinetti CF. Longitudinally extensive transverse myelitis. Curr Opin Neurol 2014;27(3):279\u2013289. doi:10.1097\/WCO.0000000000000093.","journal-title":"Curr Opin Neurol"},{"key":"e_1_3_1_62_2","article-title":"Differentiating neuromyelitis optica from other causes of longitudinally extensive transverse myelitis on spinal magnetic resonance imaging [published online ahead of print July 24, 2015]","author":"Pekcevik Y","unstructured":"Pekcevik Y Mitchell CH Mealy MA Differentiating neuromyelitis optica from other causes of longitudinally extensive transverse myelitis on spinal magnetic resonance imaging [published online ahead of print July 24, 2015]. Mult Scler. doi:10.1177\/1352458515591069.","journal-title":"Mult Scler"},{"issue":"3","key":"e_1_3_1_63_2","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3109\/08916934.2014.883501","article-title":"A review of the current literature and a guide to the early diagnosis of autoimmune disorders associated with neuromyelitis optica","volume":"47","author":"Iyer A","year":"2014","unstructured":"Iyer A Elsone L Appleton R Jacob A. A review of the current literature and a guide to the early diagnosis of autoimmune disorders associated with neuromyelitis optica. Autoimmunity 2014;47(3):154\u2013161. doi:10.3109\/08916934.2014.883501.","journal-title":"Autoimmunity"},{"issue":"1","key":"e_1_3_1_64_2","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1001\/archneurol.2007.17","article-title":"Neuromyelitis optica and non organ-specific autoimmunity","volume":"65","author":"Pittock SJ","year":"2008","unstructured":"Pittock SJ Lennon VA de Seze J Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol 2008;65(1):78\u201383. doi:10.1001\/archneurol.2007.17.","journal-title":"Arch Neurol"},{"issue":"6","key":"e_1_3_1_65_2","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/1531-8249(199912)46:6<878::AID-ANA10>3.0.CO;2-Q","article-title":"A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease","volume":"46","author":"Weinshenker BG","year":"1999","unstructured":"Weinshenker BG O\u2019Brien PC Petterson TM A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999;46(6):878\u2013886. doi:10.1002\/1531-8249(199912)46:6<878::AID-ANA10>3.0.CO;2-Q.","journal-title":"Ann Neurol"},{"issue":"2","key":"e_1_3_1_66_2","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/1352458515581438","article-title":"Treatment of acute relapses in neuromyelitis optica: steroids alone versus steroids plus plasma exchange","volume":"22","author":"Abboud H","year":"2016","unstructured":"Abboud H Petrak A Mealy M Treatment of acute relapses in neuromyelitis optica: steroids alone versus steroids plus plasma exchange. Mult Scler 2016;22(2):185\u2013192. doi:10.1177\/1352458515581438.","journal-title":"Mult Scler"},{"issue":"1","key":"e_1_3_1_67_2","first-page":"S33","article-title":"Neuromyelitis optica: potential roles for intravenous immunoglobulin","volume":"33","author":"Wingerchuk DM","year":"2012","unstructured":"Wingerchuk DM. Neuromyelitis optica: potential roles for intravenous immunoglobulin. J Clin Immunol 2012;33(suppl 1):S33\u2013S37. doi:10.1007\/s10875-012-9796-7.","journal-title":"J Clin Immunol"},{"issue":"4","key":"e_1_3_1_68_2","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1177\/1352458513495938","article-title":"Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients","volume":"20","author":"Elsone L","year":"2014","unstructured":"Elsone L Panicker J Mutch K Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients. Mult Scler 2014;20(4):501\u2013504. doi:10.1177\/1352458513495938.","journal-title":"Mult Scler"},{"issue":"6","key":"e_1_3_1_69_2","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.jaci.2008.08.033","article-title":"Intravenous immunoglobulin: adverse reactions and management","volume":"122","author":"Bonilla FA","year":"2008","unstructured":"Bonilla FA. Intravenous immunoglobulin: adverse reactions and management. J Allergy Clin Immunol 2008;122(6):1238\u20131239. doi:10.1016\/j.jaci.2008.08.033.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"e_1_3_1_70_2","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1212\/WNL.51.4.1219","article-title":"Devic\u2019s neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine","volume":"51","author":"Mandler RN","year":"1998","unstructured":"Mandler RN Ahmed W Dencoff JE. Devic\u2019s neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology 1998;51(4):1219\u20131220. doi:10.1212\/WNL.51.4.1219.","journal-title":"Neurology"},{"issue":"7","key":"e_1_3_1_71_2","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1212\/WNL.0b013e31822a2780","article-title":"Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica","volume":"77","author":"Costanzi C","year":"2011","unstructured":"Costanzi C Matiello M Lucchinetti CF Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology 2011;77(7):659\u2013666. doi:10.1212\/WNL.0b013e31822a2780.","journal-title":"Neurology"},{"issue":"9","key":"e_1_3_1_72_2","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1001\/archneurol.2010.203","article-title":"Neuromyelitis optica treatment: analysis of 36 patients","volume":"67","author":"Bichuetti DB","year":"2010","unstructured":"Bichuetti DB Lobato de Oliveira EM Oliveira DM Neuromyelitis optica treatment: analysis of 36 patients. Arch Neurol 2010;67(9):1131\u20131136. doi:10.1001\/archneurol.2010.203.","journal-title":"Arch Neurol"},{"issue":"6","key":"e_1_3_1_73_2","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/j.1468-1331.2009.02928.x","article-title":"Relapsing neuromyelitis optica: demographic and clinical features in Iranian patients","volume":"17","author":"Sahraian MA","year":"2010","unstructured":"Sahraian MA Moinfar Z Khorramnia S Ebrahim MM. Relapsing neuromyelitis optica: demographic and clinical features in Iranian patients. Eur J Neurol 2010;17(6):794\u2013799. doi:10.1111\/j.1468-1331.2009.02928.x.","journal-title":"Eur J Neurol"},{"issue":"7","key":"e_1_3_1_74_2","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.jocn.2015.01.028","article-title":"Azathioprine plus corticosteroid treatment in Chinese patients with neuromyelitis optica","volume":"22","author":"Qiu W","year":"2015","unstructured":"Qiu W Kermode AG Li R Azathioprine plus corticosteroid treatment in Chinese patients with neuromyelitis optica. J Clin Neurosci 2015;22(7):1178\u20131182. doi:10.1016\/j.jocn.2015.01.028.","journal-title":"J Clin Neurosci"},{"issue":"11","key":"e_1_3_1_75_2","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1177\/1352458514525870","article-title":"Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK","volume":"20","author":"Elsone L","year":"2014","unstructured":"Elsone L Kitley J Luppe S Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK. Mult Scler 2014;20(11):1533\u20131540. doi:10.1177\/1352458514525870.","journal-title":"Mult Scler"},{"key":"e_1_3_1_76_2","unstructured":"IMURAN (azathioprine). Product Information. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/016324s034s035lbl.pdf. Accessed April 3 2016."},{"issue":"5","key":"e_1_3_1_77_2","first-page":"651","article-title":"Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity","volume":"32","author":"Weinshilboum RM","year":"1980","unstructured":"Weinshilboum RM Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980;32(5):651\u2013662.","journal-title":"Am J Hum Genet"},{"issue":"11","key":"e_1_3_1_78_2","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1001\/jamaneurol.2014.2057","article-title":"Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder","volume":"71","author":"Huh SY","year":"2014","unstructured":"Huh SY Kim SH Hyun JW Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder. JAMA Neurol 2014;71(11):1372\u20131378. doi:10.1001\/jamaneurol.2014.2057.","journal-title":"JAMA Neurol"},{"issue":"9","key":"e_1_3_1_79_2","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/archneurol.2009.175","article-title":"Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients","volume":"66","author":"Jacob A","year":"2009","unstructured":"Jacob A Matiello M Weinshenker BG Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol 2009;66(9):1128\u20131133. doi:10.1001\/archneurol.2009.175.","journal-title":"Arch Neurol"},{"issue":"3","key":"e_1_3_1_80_2","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jamaneurol.2013.5699","article-title":"Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy","volume":"71","author":"Mealy MA","year":"2014","unstructured":"Mealy MA Wingerchuk DM Palace J Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol 2014;71(3):324\u2013330. doi:10.1001\/jamaneurol.2013.5699.","journal-title":"JAMA Neurol"},{"key":"e_1_3_1_81_2","unstructured":"CellCept\u00ae (mycophenolate mofetil capsules). Product Information. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/050722s021 050723s019 050758s019 050759s024lbl.pdf. Accessed April 3 2016."},{"issue":"7","key":"e_1_3_1_82_2","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1212\/01.WNL.0000159399.81861.D5","article-title":"An open label study of the effects of rituximab in neuromyelitis optica","volume":"64","author":"Cree BA","year":"2005","unstructured":"Cree BA Lamb S Morgan K An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005;64(7):1270\u20131272. doi:10.1212\/01.WNL.0000159399.81861.D5.","journal-title":"Neurology"},{"issue":"11","key":"e_1_3_1_83_2","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1001\/archneurol.2011.154","article-title":"Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years","volume":"68","author":"Kim SH","year":"2011","unstructured":"Kim SH Kim W Li XF Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol 2011;68(11):1412\u20131420. doi:10.1001\/archneurol.2011.154.","journal-title":"Arch Neurol"},{"key":"e_1_3_1_84_2","article-title":"Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients [published online ahead of print July 21, 2015","author":"Radaelli M","unstructured":"Radaelli M Moiola L Sangalli F Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients [published online ahead of print July 21, 2015. Mult Scler. doi:10.1177\/1352458515594042.","journal-title":"Mult Scler."},{"issue":"11","key":"e_1_3_1_85_2","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1001\/archneur.65.11.noc80069","article-title":"Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients","volume":"65","author":"Jacob A","year":"2008","unstructured":"Jacob A Weinshenker BG Violich I Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 2008;65(11):1443\u20131448. doi:10.1001\/archneur.65.11.noc80069.","journal-title":"Arch Neurol"},{"issue":"10","key":"e_1_3_1_86_2","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1177\/1352458511404586","article-title":"Impact of rituximab on relapse rate and disability in neuromyelitis optica","volume":"17","author":"Bedi GS","year":"2011","unstructured":"Bedi GS Brown AD Delgado SR Impact of rituximab on relapse rate and disability in neuromyelitis optica. Mult Scler 2011;17(10):1225\u20131230. doi:10.1177\/1352458511404586.","journal-title":"Mult Scler"},{"issue":"9","key":"e_1_3_1_87_2","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamaneurol.2013.3071","article-title":"A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder","volume":"70","author":"Kim SH","year":"2013","unstructured":"Kim SH Huh SY Lee SJ A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol 2013;70(9):1110\u20131117. doi:10.1001\/jamaneurol.2013.3071.","journal-title":"JAMA Neurol"},{"issue":"10","key":"e_1_3_1_88_2","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1007\/s00415-015-7852-y","article-title":"Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability","volume":"262","author":"Z\u00e9phir H","year":"2015","unstructured":"Z\u00e9phir H Bernard-Valnet R Lebrun C Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability. J Neurol 2015;262(10):2329\u20132335. doi:10.1007\/s00415-015-7852-y.","journal-title":"J Neurol"},{"issue":"25","key":"e_1_3_1_89_2","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards JC","year":"2004","unstructured":"Edwards JC Szczepanski L Szechinski J Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350(25):2572\u20132581. doi:10.1056\/NEJMoa032534.","journal-title":"N Engl J Med"},{"issue":"6","key":"e_1_3_1_90_2","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin\u2019s lymphoma","volume":"90","author":"Maloney DG","year":"1997","unstructured":"Maloney DG Grillo-L\u00f3pez AJ White CA IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin\u2019s lymphoma. Blood 1997;90(6):2188\u20132195.","journal-title":"Blood"},{"issue":"8","key":"e_1_3_1_91_2","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1212\/WNL.0b013e3182a1aac7","article-title":"Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica","volume":"81","author":"Yang CS","year":"2013","unstructured":"Yang CS Yang L Li T Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica. Neurology 2013;81(8):710\u2013713. doi:10.1212\/WNL.0b013e3182a1aac7.","journal-title":"Neurology"},{"issue":"7","key":"e_1_3_1_92_2","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.jocn.2010.12.011","article-title":"Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels","volume":"18","author":"Nakashima I","year":"2011","unstructured":"Nakashima I Takahashi T Cree BA Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels. J Clin Neurosci 2011;18(7):997\u2013998. doi:10.1016\/j.jocn.2010.12.011.","journal-title":"J Clin Neurosci"},{"key":"e_1_3_1_93_2","unstructured":"RITUXAN (rituximab) injection for intravenous use. Prescribing Information. www.gene.com\/download\/pdf\/rituxan_prescribing.pdf. Accessed April 3 2016."},{"key":"e_1_3_1_94_2","article-title":"Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints [published online ahead of print June 3, 2015]","author":"Jeong IH","unstructured":"Jeong IH Park B Kim SH Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints [published online ahead of print June 3, 2015]. Mult Scler. doi:10.1177\/1352458515587752.","journal-title":"Mult Scler"},{"issue":"9","key":"e_1_3_1_95_2","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1001\/jamaneurol.2015.1276","article-title":"Treatment outcomes with rituximab in 100 patients with neuromyelitis optica: influence of FCGR3A polymorphisms on the therapeutic response to rituximab","volume":"72","author":"Kim SH","year":"2015","unstructured":"Kim SH Jeong IH Hyun JW Treatment outcomes with rituximab in 100 patients with neuromyelitis optica: influence of FCGR3A polymorphisms on the therapeutic response to rituximab. JAMA Neurol 2015;72(9):989\u2013995. doi:10.1001\/jamaneurol.2015.1276.","journal-title":"JAMA Neurol"},{"key":"e_1_3_1_96_2","unstructured":"ClinicalTrials.gov. Maintenance Plasma Exchange for Neuromyelitis Optica (MultiPLEX). www.clinicaltrials.gov\/ct2\/show\/NCT01500681. Accessed April 3 2016."},{"issue":"17","key":"e_1_3_1_97_2","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1212\/WNL.0000000000001520","article-title":"Challenges and opportunities in designing clinical trials for neuromyelitis optica","volume":"84","author":"Weinshenker BG","year":"2015","unstructured":"Weinshenker BG Barron G Behne JM Challenges and opportunities in designing clinical trials for neuromyelitis optica. Neurology 2015;84(17):1805\u20131815. doi:10.1212\/WNL.0000000000001520.","journal-title":"Neurology"},{"key":"e_1_3_1_98_2","unstructured":"Clinicaltrials.gov. Accessed April 3 2016."},{"issue":"6","key":"e_1_3_1_99_2","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S1474-4422(13)70076-0","article-title":"Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study","volume":"12","author":"Pittock SJ","year":"2013","unstructured":"Pittock SJ Lennon VA McKeon A Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol 2013;12(6):554\u2013562. doi:10.1016\/S1474-4422(13)70076-0.","journal-title":"Lancet Neurol"},{"issue":"15","key":"e_1_3_1_100_2","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1212\/WNL.0000000000000317","article-title":"Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study","volume":"82","author":"Araki M","year":"2014","unstructured":"Araki M Matsuoka T Miyamoto K Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study. Neurology 2014;82(15):1302\u20131306. doi:10.1212\/WNL.0000000000000317.","journal-title":"Neurology"},{"issue":"7","key":"e_1_3_1_101_2","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1001\/jamaneurol.2015.0533","article-title":"Long-term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder","volume":"72","author":"Ringelstein M","year":"2015","unstructured":"Ringelstein M Ayzenberg I Harmel J Long-term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder. JAMA Neurol 2015;72(7):756\u2013763. doi:10.1001\/jamaneurol.2015.0533.","journal-title":"JAMA Neurol"},{"issue":"3","key":"e_1_3_1_102_2","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1212\/CON.0000000000000325","article-title":"Symptom management and lifestyle modifications in multiple sclerosis","volume":"22","author":"Coyle PK","year":"2016","unstructured":"Coyle PK. Symptom management and lifestyle modifications in multiple sclerosis. Continuum (Minneap Minn) 2016;22(3 Multiple Sclerosis and Other Demyelinating Diseases):815\u2013836.","journal-title":"Continuum (Minneap Minn)"},{"issue":"11","key":"e_1_3_1_103_2","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1001\/archneurol.2012.768","article-title":"Association of neuromyelitis optica with severe and intractable pain","volume":"69","author":"Qian P","year":"2012","unstructured":"Qian P Lancia S Alvarez E Association of neuromyelitis optica with severe and intractable pain. Arch Neurol 2012;69(11):1482\u20131487. doi:10.1001\/archneurol.2012.768.","journal-title":"Arch Neurol"}],"container-title":["Continuum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00132979-201606000-00015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T14:05:28Z","timestamp":1752156328000},"score":1,"resource":{"primary":{"URL":"https:\/\/continuum.aan.com\/doi\/10.1212\/CON.0000000000000337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":102,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["10.1212\/CON.0000000000000337"],"URL":"https:\/\/doi.org\/10.1212\/con.0000000000000337","relation":{},"ISSN":["1080-2371","1538-6899"],"issn-type":[{"value":"1080-2371","type":"print"},{"value":"1538-6899","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6]]}}}